Consequently, EZH2 inhibitor-resistant ARID1A-mutated cells become highly sensitive to BCL2 inhibitors like ABT263 suggesting that BCL2 inhibition alone or in combination with EZH2 inhibition represents an improved therapeutic strategy for ARID1A-mutated cancers. The gene discussed is BCL2; the disease is cancer.